A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

Stopped Based on lack of efficacy in PAI2003, sponsor made the decision to discontinue the trial.

Conditions

• Low Back Pain
• Low Back Pain, Recurrent

Interventions

• DRUG: JNJ-42160443 3 mg
• DRUG: JNJ-42160443 1 mg
• DRUG: JNJ-42160443 6 mg/3mg
• DRUG: JNJ-42160443 10 mg
• DRUG: Matching Placebo

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.